Jamjoom Pharma Lowers 2026 Revenue Growth Guidance to 7%-9%, Shifts Growth Drivers to 2027

Jamjoom Pharmaceuticals Factory Co. Lowered its 2026 revenue growth target to 7%-9% and revised its 2026 net profit guidance to 10%-12%, while pushing its growth drivers to 2027. Argaam reported the guidance revision on October 25, 2026.

Jamjoom Pharma's Revised 2026 Guidance

Jamjoom Pharma is a Saudi pharmaceutical company listed on Tadawul. The company said it lowered its 2026 revenue growth target to 7%-9%. It also said it revised its 2026 net profit guidance to 10%-12%. The company said it pushed its growth drivers to 2027.

Earlier Deals and Earnings

In July 2026, Jamjoom Pharma signed a binding share subscription deal with Pharmaceutical Investment Co. (Lifera) for participation in Biologics Co., a special purpose vehicle, Argaam reported. The company also intended to acquire a 49% stake in Biologics (Biologyx), a company established by Livera, a biopharmaceutical firm wholly owned by the Saudi Public Investment Fund, through a subscription to 4,900 new shares at SAR 100 per share, Sahmcapital reported. Idorsia Ltd entered an exclusive agreement with Jamjoom Pharma for the distribution and commercialization of QUVIVIQ (daridorexant), Idorsia's insomnia treatment, in Saudi Arabia and the Levant region, GlobeNewswire reported.

Jamjoom Pharma reported a second-quarter profit of 137.6 million riyals, according to a newswire report cited by AInvest. The company's board of directors decided on July 21, 2026, to distribute a 22% cash dividend (SAR 2.2 per share) for the first half of 2026, Argaam reported. Jamjoom Pharma's Algerian joint venture secured SAR 110.7 million ($29.5 million) in short-term loan and letter of credit facilities from Societe Generale and Al Baraka Bank, Zawya reported.

What to Watch Next

Jamjoom Pharma's growth drivers are now set for 2027, according to Argaam. The company's 2026 revenue growth target stands at 7%-9%, and its 2026 net profit guidance stands at 10%-12%.